# A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

> **NCT00810199** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 556 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]
- **DRUG:** methotrexate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00810199
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-08
- **Final completion:** 2013-01
- **Target enrollment:** 556 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00810199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00810199, "A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00810199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*